CLINICAL STUDY REPORT
Cardiovitine

EFFECTIVENESS OF "CARDIOVITINЕ" IN THE COMPREHENSIVE TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION

Abbreviated Version
Original Report: DOWNLOAD

Abstract
Arterial hypertension is one of the most common chronic non-specific diseases in humans, accounting for 30% of all fatal cases according to the World Health Organization. The aim of this study was to evaluate the effectiveness of "Cardiovitin" in the comprehensive treatment of arterial hypertension.

Methods
The study involved twenty patients: seventeen women (average age – 64.5±8.7 years, average weight – 77.8±11.4 kg) and three men (average age – 54.6±12.4 years, average weight – 114±40.2 kg). The examination program before and after treatment included a questionnaire, medical history, study of hypertension risk factors, ECG, complete blood count, urinalysis, and blood biochemical tests. Statistical analysis was performed using the “Statistica 6.0” software. Differences with p<0.05 were considered statistically significant.

Results
There was a statistically significant reduction in systolic pressure to 120.0 (120.0-130.0) with p<0.05, total cholesterol to 5.6 (4.6-6.4), and LDL cholesterol to 3.2 (3.1-3.5) with p<0.05 after 2 months of therapy with "Cardiovitin" in addition to standard antihypertensive therapy.

Conclusion
The results indicate the effectiveness of including "Cardiovitin" in the basic antihypertensive therapy regimen as a source of bioflavonoids, which help stabilize the vascular wall.

Introduction
Arterial hypertension is one of the most common chronic non-specific diseases in humans, accounting for 30% of all fatal cases according to the World Health Organization. Available statistical data for Russia indicate that hypertension affects at least 40% of the population, 58% of women, and 37% of men. Only 48% of women and 21% of men receive regular treatment, with target blood pressure levels achieved in 17.5% of women and 5.7% of men . Currently, the prevalence of arterial hypertension is epidemic, and hypertension can be considered a large-scale non-infectious pandemic. The necessity to combat hypertension is due to it being one of the leading causes of disability and death. Prolonged high blood pressure leads to damage to target organs and the development of cardiovascular complications - heart failure, myocardial infarction, stroke, and kidney failure . The main indicator of the effectiveness of hypertension treatment is achieving and maintaining disease control (achieving target blood pressure levels). The wide prevalence and socio-economic impact of hypertension on society and each patient requires prevention, timely identification of risk factors, adequate therapy, and prevention of complications . The dietary supplement "Cardiovitin" is a natural antioxidant containing 40 mg of dihydroquercetin (taxifolin), 120 mg of Acerola plant extract 25%, at least 30 mg of vitamin C, and excipients in one capsule. Dihydroquercetin is known to have antioxidant, capillary-protective, hemoregulatory, antiplatelet, and anti-inflammatory activity . Dihydroquercetin is an effective antioxidant that interrupts lipid peroxidation processes in cell membranes, penetrates the cytoplasm, and protects cells from the damaging effects of free radicals. It effectively corrects disturbances in various parts of the body's antioxidant system, providing comprehensive antioxidant protection, actively preventing oxidative stress, degenerative-dystrophic processes in tissues, and early cell aging, and effectively counteracting the destructive factors of modern ecology, production, diet, and lifestyle . Dihydroquercetin has a capillary-protective effect, reducing permeability and fragility of capillaries, improving microcirculation, helping to inhibit the action of hyaluronidase and collagenase enzymes that weaken the connective tissue of blood vessel walls and other systems, but activates proline hydroxylase, which promotes "maturation" of collagen (a substrate of proline hydroxylase), maintaining strength, elasticity, and normalizing vascular wall permeability . By inhibiting free radical lipid peroxidation processes in biomembranes (interrupting the chains of interactions between peroxides and nitroperoxides with lipids and liposaccharides), dihydroquercetin stabilizes cell membranes, helps normalize capillary permeability, and prevents the development of dystrophic and sclerotic changes in tissues. On the water-lipid surface of the cell membrane, the structure, quantity, and arrangement of hydroxyl groups of the dihydroquercetin molecule with a predominance of hydrophilic groups determine the formation of hydrogen bonds with the polar external groups of membrane lipid molecules, protecting the membrane from external damage . The membrane-stabilizing effect of dihydroquercetin and its redox properties promote effective tissue function, oxygen utilization, and ATP synthesis in mitochondria. Along with stabilizing red blood cell membranes and improving their oxygen transport function, these effects determine the antihypoxic and antihemolytic properties of dihydroquercetin, which contribute to enhancing the oxygen and energy supply of cells. Dihydroquercetin has a statin-fibrate effect, helping to increase the blood content of so-called good cholesterol - high-density lipoproteins, and also reduces the level of triglycerides and low-density "bad" cholesterol. Dihydroquercetin enhances insulin signals within the cell. The numerous beneficial effects of dihydroquercetin as a fibrate model suggest the use of this ingredient for the prevention of dyslipidemia and reducing the risk of cardiovascular diseases and their complications in individuals with metabolic syndrome. The ability of the dihydroquercetin molecule to modulate the response of intracellular receptors promotes glucose utilization by cells, enhances insulin sensitivity, improves lipid metabolism and lipid biomarkers, reduces the tendency to gain weight, and positively affects endothelial function, reduces the level of inflammatory reactions, and other risk factors for cardiovascular diseases . As an addition to cardiovascular therapy, dihydroquercetin positively influences the clinical course of hypertension. There was a reduction in blood pressure, improvement in blood microcirculation, reduction in congestion, and improvement in patient well-being (reduction in headache frequency, head noise, dizziness, and coordination disorders) . The endothelium plays a key role in controlling vascular tone, regulating vessel lumen depending on blood flow rate and pressure on the vessel wall, and the metabolic needs of the tissue. Therefore, it is extremely important to seek new drugs that help restore the endothelium and normalize microcirculation . "Cardiovitin" is one such drug. The aim of this study was to evaluate the effectiveness of "Cardiovitin" in the comprehensive treatment of patients with arterial hypertension.

Methods
The study involved 20 patients (aged 54.6–64.5 years, weighing 77.8–114 kg). All patients received standard antihypertensive therapy and "Cardiovitin". The observation period was 2 months. Before and after treatment, the examination included: questionnaire, medical history, study of hypertension risk factors, ECG, complete blood count, urinalysis, and blood biochemical tests. Statistical analysis was performed using the “Statistica 6.0” software. Differences with p<0.05 were considered statistically significant.

Results
After 2 months of therapy with "Cardiovitin" in addition to standard antihypertensive therapy, there was a statistically significant reduction in:
  • Systolic pressure – 120.0 (120.0-130.0) with p<0.05;
  • Total cholesterol – 5.6 (4.6-6.4);
  • LDL cholesterol – 3.2 (3.1-3.5) with p<0.05.
Conclusion
The inclusion of "Cardiovitin" in the basic antihypertensive therapy regimen contributed to improved blood pressure control, reduced cholesterol and low-density lipoprotein levels, indicating its effectiveness as a source of bioflavonoids that stabilize the vascular wall.

References
  1. J, Jordan, C, Kurschat, H, Reuter, Arterial Hypertension, Dtsch Arztebl Int. 20, 115(33-34), 557-568 (2018) doi: 10.3238/arztebl.2018.0557
  2. L. A. Strizhakov, S. A. Babanov, Arterial hypertension at the workplace: risk factors and the population value, Arkh. 20, 90(9), 138-143 (2018) doi: 10.26442/terarkh2018909138-143
  3. K. Dumor, M. Shoemaker-Moyle, R. Nistala, Arterial Stiffness in Hypertension: an Update, Curr Hypertens Rep, 4, 20(8),72 (2018) doi: 10.1007/s11906-018-0867-x
  4. R. Mrowka, Arterial hypertension, Acta Physiol (Oxf), 219(4), 697-699 (2017) doi: 10.1111/apha.12855.
  5. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Russian Journal of Cardiology, 23(12), 143-228 (2018) doi: 10.1093/eurheartj/ehy339
  6. I. Chazova, Arterial hypertension in the light of current recommendations, Ter Arkh, 20, 90(9), 4-7 (2018) doi: 10.26442/terarkh20189094-7
  7. U. O. Wenzel, M. Bode, J. Köhl, H. Am J. Ehmke, A pathogenic role of complement in arterial hypertension and hypertensive end organ damage, Physiol Heart Circ Physiol. 1, 312(3), 349-354 (2017) doi: 10.1152/ajpheart.00759.2016. Epub
  8. I. Chazova, Yu. Zhernakova, Diagnosis and treatment of Arterial hypertension [Guidelines]. Sistemnyye gipertenzii, 16(1), 6-31 (2019) doi: 10.26442/2075082X.2019.1.190179
  9. R. Patel, B. Mistry Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem, 15, 889-904 (2018) doi: 10.1016/j.ejmech.2018.06.053.
  10. K. Manigandan, R. Jayaraj, N. Elangovan, Taxifolin ameliorates 1, 2- dimethylhydrazine induced cell proliferation and redox avulsions in mice colon carcinogenesi. Biomedicine & Preventive Nutrition, 4, 499-509 (2014) http://dx.doi.org/10.1016/j.bionut.2014.08.00
  11. Y. Zhang, J. Yu, X. D. Dong, H. Y. Ji, Molecules, Research on Characteristics, Antioxidant and Antitumor Activities of Dihydroquercetin and Its Complexes, 22, 23(1), 20 (2017) doi: 10.3390/molecules23010020
  12. K. Asmi, T. Lakshmi, S. Balusamy, Therapeutic aspects of taxifolin – An update. Journal of Advanced Pharmacy Education & Research. Published by SPER Publications, 7, 187-189 (2017) https://japer.in/storage/models/article/
  13. M. B. Plotnikov, O. I. Aliev, A. V. Sidekhmenova, Dihydroquercetin Improves Microvascularization and Microcirculation in the Brain Cortex of SHR Rats during the Development of Arterial Hypertension, Bull Exp Biol Med, 163(1), 57-60 (2017) doi: 10.1007/s10517-017-3737-7
  14. Z. Shu, Y. Yang, L. Yang, Cardioprotective effects of dihydroquercetin against ischemia reperfusion injury by inhibiting oxidative stress and endoplasmic reticulum stress-induced apoptosis via the PI3K/Akt pathway, Food Funct, 22, 10(1), 203-215 (2019) doi: 10.1039/c8fo01256c
  15. D. Konukoglu, H. Uzun, Endothelial Dysfunction and Hypertension, Adv Exp Med Biol, 956, 511-540 (2017) doi: 10.1007/5584_2016_90
  16. A. Daiber, S. Steven, A. Weber, Targeting vascular (endothelial) dysfunction, Br J Pharmacol, 174(12), 1591-1619 (2017) doi: 10.1111/bph.13517. Epub 2016 Jul 4.